TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16490024

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 14992341

Group type: EXPERIMENTAL
Intervention: Active FES‐assisted standing (AS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Frame‐supported passive standing (PS)
Number of subjects: 15
Study: 11121916

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Aspirin 2600 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 8970342

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms twice a day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice a day)
Number of subjects: 12
Study: 1306041

Group type: EXPERIMENTAL
Intervention: Lignocaine 3 ml 1%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Isotonic saline 3 ml
Number of subjects: 28
Study: 6391418

Group type: EXPERIMENTAL
Intervention: Patient education group (receiving standard inpatient medical care + formal education program)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (receiving only standard inpatient medical care)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Patient education group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 30458263

Group type: EXPERIMENTAL
Intervention: Group B (awareness of alcohol consumption focus)
Number of subjects: 5478

Group type: EXPERIMENTAL
Intervention: Group C (additional questions on alcohol use)
Number of subjects: 5478

Group type: COMPARATOR
Intervention: Group A (control group, lifestyle survey only)
Number of subjects: 5478
Study: 29891726

Group type: EXPERIMENTAL
Intervention: Direct mail materials and a $20 incentive for screening
Number of subjects: 116407
Study: 25627152

Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study: 23846809

Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Diabetic subjects with neuropathy
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: NSE levels
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Optimal cutoff point for serum NSE levels
Number of subjects: 568
Study: 21288803

Group type: EXPERIMENTAL
Intervention: Pentavac(®) (new vaccine)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Easyfive(®) (available in the market)
Number of subjects: 484
Study: 19918088

Group type: EXPERIMENTAL
Intervention: Telephone-delivered collaborative care
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study: 16450340

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/day
Number of subjects: 404

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study: 14992912

Group type: EXPERIMENTAL
Intervention: 1 U of fresh frozen plasma (FFP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No fresh frozen plasma (no FFP)
Number of subjects: 20
Study: 11401627

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-beta-1a
Number of subjects: 0
Study: 12318240

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 46
Study: 3303244

Group type: EXPERIMENTAL
Intervention: Ramified amino acids (24 g in a 750 ml solution) infused daily for 10 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sorbitol (5% solution, 750 ml) infused daily for 10 days
Number of subjects: 20
Study: 28776922

Group type: EXPERIMENTAL
Intervention: Subcutaneous exendin (9-39) injection
Number of subjects: 9
Study: 26922904

Group type: EXPERIMENTAL
Intervention: e‐learning educational program
Number of subjects: 697

Group type: COMPARATOR
Intervention: basic geriatric pharmacology notions (Control)
Number of subjects: 697
Study: 26205091

Group type: EXPERIMENTAL
Intervention: Sirolimus (n=8)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tacrolimus (n=10)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 18
Study: 23419098

Group type: EXPERIMENTAL
Intervention: Nasal intermittent mandatory ventilation (NIMV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 40
Study: 21138693

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with thoracic epidural anesthesia (Group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia (Group B)
Number of subjects: 120
Study: 18234554

Group type: EXPERIMENTAL
Intervention: Plasma levels of MMP-2 and TIMP-1
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Plasma levels of MMP-9
Number of subjects: 184

Group type: COMPARATOR
Intervention: Angiotensin II, epinephrine, norepinephrine
Number of subjects: 184
Study: 16464887

Group type: EXPERIMENTAL
Intervention: On-line haemodiafiltration with acetate (3 mmol/l)
Number of subjects: 12

Group type: COMPARATOR
Intervention: On-line haemodiafiltration without acetate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: On-line haemodiafiltration with acetate
Number of subjects: 12
Study: 12694711

Group type: EXPERIMENTAL
Intervention: Patients who agreed to participate in the clinical trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients who refused to participate in the clinical trial
Number of subjects: 0
Study: 10610746

Group type: EXPERIMENTAL
Intervention: Oral amiodarone 400 mg/day for 1 month before and 200 mg/day for 2 months after cardioversion
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Oral diltiazem 180 mg/day for 1 month before and 2 months after cardioversion and potassium infusion
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (oral diltiazem 180 mg/day for 1 month before and 2 months after cardioversion)
Number of subjects: 92
Study: 9093005

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide 0.25 pmol min‐1 kg‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide 0.5 pmol min‐1 kg‐1
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide 0.5 pmol min‐1 kg‐1 with SCH 32615 pretreatment
Number of subjects: 8
Study: 8436001

Group type: EXPERIMENTAL
Intervention: Levonorgestrel triphasic (LNG)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Norethindrone triphasic (NET)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study: 3529953

Group type: EXPERIMENTAL
Intervention: Regular aspirin (325 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (325 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 29432648

Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg, 10 drops orally, three times daily for 12 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Artificial saliva (10 drops orally, three times daily for 12 weeks)
Number of subjects: 72
Study: 26678717

Group type: EXPERIMENTAL
Intervention: Neuromuscular taping (NMT) and standard physical therapy programme (SPTP)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard physical therapy programme (SPTP)
Number of subjects: 32
Study: 24476472

Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isocaloric, isovolumetric placebo control orange juice
Number of subjects: 12
Study: 22820158

Group type: EXPERIMENTAL
Intervention: Yoga exercise session
Number of subjects: 30

Group type: COMPARATOR
Intervention: Aerobic exercise session
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 30
Study: 19887674

Group type: EXPERIMENTAL
Intervention: Etoricoxib (selective COX-2 inhibitor)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: NS-398 (selective COX-2 inhibitor) added in vitro
Number of subjects: 41
Study: 18248356

Group type: EXPERIMENTAL
Intervention: 2D guidance
Number of subjects: 30

Group type: COMPARATOR
Intervention: 3D angioscopy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MNS multivessel intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Magnetic guided intervention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: MNS
Number of subjects: 30
Study: 15817865

Group type: EXPERIMENTAL
Intervention: Home-based therapy with RUTF
Number of subjects: 1178

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1178
Study: 14728493

Group type: EXPERIMENTAL
Intervention: Patient-accessible electronic medical record
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10643835

Group type: EXPERIMENTAL
Intervention: Estrogen Replacement Therapy (ERT)
Number of subjects: 23
Study: 8876406

Group type: EXPERIMENTAL
Intervention: Educational programme for nurses
Number of subjects: 0
Study: 1445513

Group type: EXPERIMENTAL
Intervention: Diuretic (hydrochlorothiazide 25 mg or 50 mg plus amiloride 2.5 mg or 5 mg daily)
Number of subjects: 4396

Group type: EXPERIMENTAL
Intervention: Beta blocker (atenolol 50 mg daily)
Number of subjects: 4396

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4396
Study: 4061343

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg zinc added to daily vitamin and mineral supplements)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (similar daily vitamin and mineral supplements without zinc)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 138
Study: 31796025

Group type: EXPERIMENTAL
Intervention: Biannual azithromycin distribution
Number of subjects: 991

Group type: COMPARATOR
Intervention: Annual azithromycin distribution
Number of subjects: 991
Study: 30236795

Group type: EXPERIMENTAL
Intervention: Web-based APP (TRAFIC) for electronic PROMs collection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (not utilizing the APP)
Number of subjects: 100
Study: 27510346

Group type: EXPERIMENTAL
Intervention: HIV testing within 30 days of a positive STI test
Number of subjects: 15260

Group type: EXPERIMENTAL
Intervention: HIV testing within 90 days of a positive STI test
Number of subjects: 15260

Group type: EXPERIMENTAL
Intervention: Syphilis testing within 30 days of a positive STI test
Number of subjects: 15260

Group type: EXPERIMENTAL
Intervention: HIV testing within 30 days of syphilis testing
Number of subjects: 15260
Study: 24849434

Group type: EXPERIMENTAL
Intervention: DC-CIK immunotherapy combined with TACE
Number of subjects: 68

Group type: COMPARATOR
Intervention: TACE alone (control group)
Number of subjects: 68
Study: 22984155

Group type: EXPERIMENTAL
Intervention: Inhaled fentanyl 25 µg
Number of subjects: 10

Group type: COMPARATOR
Intervention: IV fentanyl 25 µg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled fentanyl (50 to 300 µg)
Number of subjects: 10
Study: 20819419

Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of 2 mg/kg ropivacaine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Normal saline (placebo control)
Number of subjects: 63
Study: 18281049

Group type: EXPERIMENTAL
Intervention: Metformin treatment for 3 months
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol-cyproterone acetate (EE/CPA) treatment for 3 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study: 15309436

Group type: EXPERIMENTAL
Intervention: Vitamin B(6), B(12), and folate supplementation for 6 months
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 12421488

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg/day
Number of subjects: 211

Group type: COMPARATOR
Intervention: Omeprazole 20 mg/day
Number of subjects: 211
Study: 10598759

Group type: EXPERIMENTAL
Intervention: Topical 5-aminolaevulinic acid photodynamic therapy (ALA-PDT)
Number of subjects: 10
Study: 7564784

Group type: EXPERIMENTAL
Intervention: IFN‐alpha (6 MU three times weekly for 12‐24 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IFN‐alpha
Number of subjects: 90

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 90
Study: 1940881

Group type: EXPERIMENTAL
Intervention: Gamma interferon (0.5 to 3.0 million units per day for 7 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Alpha interferon (5-6 million units daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gamma interferon (1 million units for 28 consecutive days)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both IFNs
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gamma interferon
Number of subjects: 35
Study: 6412584

Group type: EXPERIMENTAL
Intervention: Fentanyl 4 micrograms/kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diazepam 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Droperidol 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Etomidate 10 mg
Number of subjects: 10
Study: 29553287

Group type: EXPERIMENTAL
Intervention: Clear Box + Good Behavior Game (GBG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clear Box
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (typical classroom management techniques)
Number of subjects: 0
Study: 30346560

Group type: EXPERIMENTAL
Intervention: Modified S-1 treatment (reduced initial dose of S-1 by ≥ 1 level compared with the standard dose)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 370
Study: 26176649

Group type: EXPERIMENTAL
Intervention: Hot compresses (40°C) applied to the lumbar area for 5 hours daily for 2 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study: 24854458

Group type: EXPERIMENTAL
Intervention: Extended release niacin (ERN)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Extended release niacin combined with laropiprant (ERN-L)
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 22963328

Group type: EXPERIMENTAL
Intervention: Multimodal training intervention (MTI) consisting of daily endurance and twice-a-week strength training
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Multimodal training intervention (MTI)
Number of subjects: 117
Study: 19343362

Group type: EXPERIMENTAL
Intervention: Coconut and anise spray
Number of subjects: 100

Group type: COMPARATOR
Intervention: Permethrin 0.43% lotion
Number of subjects: 100
Study: 17914654

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Electrostimulation
Number of subjects: 49
Study: 15935095

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 465

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 465

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 465
Study: 12423713

Group type: EXPERIMENTAL
Intervention: Metoprolol (high-dose, 1-year course)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Carvedilol (high-dose, 1-year course)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 10437298

Group type: EXPERIMENTAL
Intervention: Bracing for Cobb angle over thirty degrees
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural history of scoliosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scoliotic population
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-operated patients with severe idiopathic scoliosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-hooks systems for surgical correction
Number of subjects: 0
Study: 8584309

Group type: EXPERIMENTAL
Intervention: Combined diphtheria-tetanus vaccine administered at 3, 5, and 12 months of age.
Number of subjects: 44
Study: 2218781

Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alpha-methyldopa
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7005521

Group type: EXPERIMENTAL
Intervention: Gold
Number of subjects: 70

Group type: COMPARATOR
Intervention: D-Penicillamine (D-Pen.)
Number of subjects: 70
Study: 30365024

Group type: EXPERIMENTAL
Intervention: Self-reported e‐cig use (times per day)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Penn State Electronic Cigarette Dependence Index (PSECDI)
Number of subjects: 259
Study: 30149476

Group type: EXPERIMENTAL
Intervention: VEGF protein expression in the proximal end of the umbilical cord
Number of subjects: 48

Group type: COMPARATOR
Intervention: VEGF protein expression in the distal end of the umbilical cord
Number of subjects: 48
Study: 29071332

Group type: EXPERIMENTAL
Intervention: Chewing ticagrelor, 180mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard oral administration of ticagrelor, 180mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups (chewing and standard oral administration)
Number of subjects: 50
Study: 25465884

Group type: EXPERIMENTAL
Intervention: Social stress condition
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study: 23949042

Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain (CKC) exercise
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain (OKC) exercise
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (routine activities, no exercise)
Number of subjects: 33
Study: 21051511

Group type: EXPERIMENTAL
Intervention: Automatic brain volume assessment using Q(Brain) software
Number of subjects: 61

Group type: COMPARATOR
Intervention: Manual brain volume assessment (reference method)
Number of subjects: 61
Study: 19592125

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study: 17466465

Group type: EXPERIMENTAL
Intervention: Behavioral intervention designed to decrease sexual and injection risk behaviors, delivered in six sessions.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention, details not specified.
Number of subjects: 0
Study: 14984453

Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.15 U/kg body weight)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Regular insulin (0.15 U/kg body weight)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normal controls (single standard meal test)
Number of subjects: 23
Study: 11157184

Group type: COMPARATOR
Intervention: AR-R15896AR 250 mg loading dose
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175

Group type: COMPARATOR
Intervention: AR-R15896AR 120 mg maintenance dose
Number of subjects: 175
Study: 10923526

Group type: EXPERIMENTAL
Intervention: Urban children
Number of subjects: 157362

Group type: EXPERIMENTAL
Intervention: Rural children
Number of subjects: 157362

Group type: EXPERIMENTAL
Intervention: Children in northern and central China
Number of subjects: 157362

Group type: EXPERIMENTAL
Intervention: Overall children
Number of subjects: 157362
Study: 7939467

Group type: EXPERIMENTAL
Intervention: Laparoscopic ligature of the spermatic veins (outpatient group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Laparoscopic ligature of the spermatic veins (hospitalised group)
Number of subjects: 24
Study: 3047887

Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29899342

Group type: EXPERIMENTAL
Intervention: Co-occurrence scenario
Number of subjects: 130

Group type: COMPARATOR
Intervention: Trait information scenario
Number of subjects: 130

Group type: COMPARATOR
Intervention: Random selection scenario
Number of subjects: 130
Study: 27364771

Group type: EXPERIMENTAL
Intervention: Veledimex (oral activator ligand) administered in Labrasol slurry and F-22 capsule formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Veledimex (oral activator ligand) administered once daily for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Veledimex taken under fed conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Veledimex (overall treatment)
Number of subjects: 0
Study: 26582847

Group type: EXPERIMENTAL
Intervention: PTC1‐2 group (post‐tetanic counts 1‐2)
Number of subjects: 72

Group type: COMPARATOR
Intervention: TOFcount1‐2 group (train‐of‐four counts 1‐2)
Number of subjects: 72
Study: 24250307

Group type: EXPERIMENTAL
Intervention: Diet regimen, exercise training, and medical treatment for two months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 80
Study: 20333393

Group type: EXPERIMENTAL
Intervention: Modified Misgav-Ladach method (MMLM)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Pfannenstiel-Kerr method (PKM)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Both MMLM and PKM
Number of subjects: 115
Study: 18344107

Group type: EXPERIMENTAL
Intervention: Sustained-release acetaminophen, 1300 mg orally q8h for 11 doses
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 17292769

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 521

Group type: COMPARATOR
Intervention: amodiaquine plus sulfadoxine-pyrimethamine
Number of subjects: 521
Study: 14969673

Group type: COMPARATOR
Intervention: Family-planning (FP) referral
Number of subjects: 474

Group type: COMPARATOR
Intervention: Advanced provision emergency contraception (APEC)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Past pregnancy rate
Number of subjects: 474

Group type: COMPARATOR
Intervention: No contraception or condoms alone
Number of subjects: 474
Study: 11878530

Group type: EXPERIMENTAL
Intervention: 4% gelatin solution (Gelofusine) 15 ml kg(‐1) i.v. (colloid group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No preload (control group)
Number of subjects: 68
Study: 9181155

Group type: EXPERIMENTAL
Intervention: 75 mg hyperbaric lidocaine 5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 mg hyperbaric lidocaine 5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both dosage groups (75 mg and 100 mg)
Number of subjects: 20
Study: 7964106

Group type: EXPERIMENTAL
Intervention: Controlled active motion regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive flexion-active extension regimen
Number of subjects: 0